Exhalation delivery system

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Thursday, November 9, 2023
ENT, FDA, Sinusitis, Food, MPH, Prescription Drug User Fee Act, SG, Telephone, Conference, GAAP, Regulation of tobacco by the U.S. Food and Drug Administration, Research, CS, OPTN, Shanda, Webcast, Ear, Exhalation delivery system, Fluticasone, Conference call, Polyp (medicine), Patient, General Administration of Sport of China, Nose, Pharmaceutical industry, Cryptocurrency, PDUFA, MD

YARDLEY, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2023, and provided operational updates.

Key Points: 
  • We are pleased with the progress we made in the third quarter towards our 2023 operating objectives while sharply reducing expenses.
  • Today’s results show that we are outperforming our initial expectations for 2023 XHANCE net revenues while operating far more efficiently and preparing our organization for a successful launch in 2024.
  • Previously, the Company expected XHANCE net revenues for the full year of 2023 to be between $64.0 to $70.0 million.
  • Members of the Company’s leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Thursday, August 10, 2023
ENT, Patent, Exhalation delivery system, SG, Ear, Conference call, OPTN, General Administration of Press and Publication, Telephone, Prescription Drug User Fee Act, GAAP, Research, Nose, Orange Book, United States Patent and Trademark Office, Sinusitis, Patient, Approved Drug Products with Therapeutic Equivalence Evaluations, Fluticasone, PDUFA, Webcast, FDA, MPH, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, MD, Conference

YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates.

Key Points: 
  • Conference call and webcast to be held today at 8:00 a.m. Eastern Time
    YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates.
  • “We are pleased with the progress we made in the second quarter of 2023 towards our strategic objectives,” stated CEO Ramy Mahmoud, MD, MPH.
  • “That means we are outperforming our initial expectations for full year 2023 XHANCE net revenues while operating far more efficiently.
  • Members of the Company’s leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Thursday, May 11, 2023
ENT, Patent, Exhalation delivery system, Ear, Conference call, OPTN, General Administration of Sport of China, Telephone, Prescription Drug User Fee Act, GAAP, Research, Nose, Orange Book, United States Patent and Trademark Office, Sinusitis, Patient, Exhalation, Approved Drug Products with Therapeutic Equivalence Evaluations, PDUFA, Webcast, FDA, MPH, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, MD, Conference

YARDLEY, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2023, and provided operational updates.

Key Points: 
  • Conference call and webcast to be held today at 8:00 a.m. Eastern Time
    YARDLEY, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2023, and provided operational updates.
  • “We are pleased with the progress we made in the first quarter of 2023 towards our strategic objectives," stated CEO Ramy Mahmoud, MD, MPH.
  • The Company expects XHANCE net revenues for the full year of 2023 to be between $62.0 to $68.0 million.
  • Members of the Company’s leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Tuesday, March 7, 2023
PDUFA, New Drug Application, Sinusitis, Reopening Ontario Act, Conference call, FDA, ENT, Safety, Telephone, Ear, Webcast, OPTN, Nose, Research, ACAAI, American College, Marketing, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, MPH, Exhalation delivery system, Exhalation, Food, GAAP, Pharmaceutical industry, Cryptocurrency, Conference, MD

YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2022, and provided recent operational highlights.

Key Points: 
  • Assuming acceptance and a standard review period the Company expects the FDA's PDUFA action date to be in December 2023.
  • For the three-month and twelve-month periods ended December 31, 2022, research and development expenses were $2.9 million and $15.3 million, respectively.
  • The net loss for the three-month period ended December 31, 2022 was $15.1 million, or $0.17 per share (basic and diluted).
  • The net loss for the twelve-month period ended December 31, 2022 was $74.8 million, or $0.87 per share (basic and diluted).

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

Retrieved on: 
Thursday, August 11, 2022
FDA, Telephone, Ear, Depression, General Administration of Sport of China, Pain scale, Inflammation, GLOBE, Third Amendment to the Constitution of Pakistan, CT, Conference call, Disease, Incidence, Research, Patient, Sinusitis, COVID-19, Company, Nasal polyp, Nose, Nasal congestion, Polyp (medicine), Reopening the Gates, OPTN, Rhinorrhea, Pressure, GAAP, Headache, NASDAQ, ENT, Exhalation delivery system, MPH, News, Webcast, Investor, Nosebleed, Fluticasone, Pharmaceutical industry, Medical imaging, Health insurance, Online gambling, MD, Conference

Conference call and webcast to be held today at 8:00 a.m. Eastern Time

Key Points: 
  • Conference call and webcast to be held today at 8:00 a.m. Eastern Time
    YARDLEY, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2022, and provided operational updates.
  • We reported confirmatory, positive topline results from ReOpen2 in June and are further encouraged by the consistency observed in key secondary and pooled results," stated CEO Peter Miller.
  • Our current business is performing well, XHANCE net revenue increased 12% in the second quarter of 2022 compared to second quarter 2021 and increased 21% on a year-to-date basis.
  • Members of the Companys leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
Tuesday, March 8, 2022
Cataract, Patient, OPTN, Pain scale, Research, Investor, Asthma, CT, FDA, General Administration of Sport of China, Exhalation delivery system, Prescription, ENT, Webcast, Company, Ear, Disease, Nosebleed, NASDAQ, Common, Clinical trial, GAAP, Sinusitis, Fluticasone, Nasal congestion, Physician, Pressure, GLOBE, Nose, Conference call, Pharmaceutical industry, Animal, Conference

The number of XHANCE (fluticasone propionate) prescriptions increased by 27% from 73,900 in the fourth quarter 2020 to 93,700 in the fourth quarter 2021.

Key Points: 
  • The number of XHANCE (fluticasone propionate) prescriptions increased by 27% from 73,900 in the fourth quarter 2020 to 93,700 in the fourth quarter 2021.
  • In addition, XHANCE prescriptions increased by 28% from 261,400 for the full year of 2020 to 335,600 for the full year of 2021.
  • The number of new prescriptions for XHANCE increased by 21% from 24,600 in the fourth quarter of 2020 to 29,900 in the fourth quarter of 2021.
  • This includes the Company's expectation that first quarter 2022 XHANCE net revenue will decrease compared to fourth quarter 2021.

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
Wednesday, August 11, 2021
Investor, General Administration of Sport of China, Prescription, Polyp (medicine), Enterprise, European Patent Office, Nose, Fluticasone, Science, Company, International Forum on Energy Security for the Future, Patient, EPO, European Patent Convention, Award, Technology, European, OPTN, Clinical trial, Conference call, Politics, Popular, International Forum of Allergy & Rhinology, Viral load, GAAP, Ear, Sinusitis, ENT, NASDAQ, Exhalation delivery system, Steroid, Webcast, GLOBE, European Inventor Award, Allergy, Council of Scientific and Industrial Research, Lithium, Pharmaceutical industry, Animal

YARDLEY, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2021, and provided operational updates.

Key Points: 
  • We are pleased with the progress we made in second quarter 2021 towards our objectives of growing XHANCE and successfully completing our chronic sinusitis program, stated CEO Peter Miller.
  • The number of total XHANCE (fluticasone propionate) prescriptions increased by 33% from 62,500 in the second quarter 2020 to 82,900 in the second quarter 2021.
  • The number of new XHANCE prescriptions increased by 55% from 18,700 in the second quarter of 2020 to 29,000 in the second quarter of 2021.
  • The Company expects to complete patient enrollment in its second clinical trial in the fourth quarter of 2021 and to have top-line results in the second quarter of 2022.

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays

Retrieved on: 
Tuesday, September 29, 2020
Anatomy, Organ systems, Medicine, Nose, Dosage forms, RTT, Sensory organs, Nasal polyp, Exhalation delivery system, Nasal spray, Sinusitis, Human nose

But unlike AR, the nasal polyps associated with chronic rhinosinusitis start deep in the nasal cavity where nasal sprays usually do not reach.

Key Points: 
  • But unlike AR, the nasal polyps associated with chronic rhinosinusitis start deep in the nasal cavity where nasal sprays usually do not reach.
  • This supports the value of using XHANCE to put medicine high and deep in the nose, where standard nasal sprays usually do not reach."
  • INDICATION AND USAGE: XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.
  • Efficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays.

Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial

Retrieved on: 
Tuesday, December 17, 2019
Health, RTT, Glucocorticoids, Organofluorides, Medicine, Fluticasone propionate, Respiratory therapy, Thioesters, Exhalation delivery system, Propionate, Food and Drug Administration

We are pleased to announce the publication of EXHANCE-3, the fourth major registration trial from the development program supporting the initial FDA approval of XHANCE, said Ramy Mahmoud, M.D., M.P.H., President and Chief Operating Officer of Optinose.

Key Points: 
  • We are pleased to announce the publication of EXHANCE-3, the fourth major registration trial from the development program supporting the initial FDA approval of XHANCE, said Ramy Mahmoud, M.D., M.P.H., President and Chief Operating Officer of Optinose.
  • The Optinose team would like to thank the investigators and patients who made this trial possible.
  • Data from this trial contributes importantly to understanding the clinical performance of XHANCE and would not be available today without their willingness to participate.
  • XHANCE combines a proprietary Optinose Exhalation Delivery System (EDS) for liquids with an aqueous suspension of microfine fluticasone propionate for topical intranasal administration
    Hypersensitivity to any ingredient in XHANCE.